Lilly Asia Ventures contributed to a $55m round that will support work on Nucleix's early-stage lung cancer biopsy.
US-headquartered liquid cancer biopsy developer Nucleix raised $55m yesterday from investors including Lilly Asia Ventures, a corporate venture capital vehicle for pharmaceutical firm Eli Lilly. Investment manager RA Capital Management led the round, which also featured Lyfe Capital, Milfam, funds and accounts managed by BlackRock, and existing backers including OrbiMed, Aurum Ventures, DSC Investment, OCI…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.